Evidence map›Paper›PMID 21852560›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2011

Focal adhesion kinase-related nonkinase inhibits vascular smooth muscle cell invasion by focal adhesion targeting, tyrosine 168 phosphorylation, and competition for p130(Cas) binding.

Yevgeniya E Koshman, Miensheng Chu, Steven J Engman, Taehoon Kim, Rekha Iyengar, Seth L Robia, Allen M Samarel

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review.Journal of experimental & clinical cancer research : CR · 2019
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yevgeniya E KoshmanCardiovascular Institute, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.
Miensheng Chu
Steven J Engman
Taehoon Kim
Rekha Iyengar
Seth L Robia
Allen M Samarel
Loyola University Chicago · US

Funding

Sarcomeric Modifications and Progressive Cardiac MaladaptationP01HL062426 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI AI, XUN · 2000 to 2020
$42.4M
Novel Approaches in Treatment of Vascular Injury Following Balloon AngioplastyF32HL096143 · NHLBI · LOYOLA UNIVERSITY CHICAGO · PI KOSHMAN, YEVGENIYA EMRE · 2010 to 2013
$128k
NHLBI NIH HHS 1F32-HL096143NHLBI NIH HHS 2P01-HL062426NHLBI NIH HHS F32 HL096143NHLBI NIH HHS P01 HL062426
6 · The paper itself

Abstract

objectiveFocal adhesion kinase-related nonkinase (FRNK), the C-terminal domain of focal adhesion kinase (FAK), is a tyrosine-phosphorylated, vascular smooth muscle cell (VSMC)-specific inhibitor of cell migration. FRNK inhibits both FAK and proline-rich tyrosine kinase 2 (PYK2) in cultured VSMCs, and both kinases may be involved in VSMC invasion during vascular remodeling. METHODS AND

resultsAdenovirally mediated gene transfer of green fluorescent protein-tagged, wild-type (wt) FRNK into balloon-injured rat carotid arteries confirmed that FRNK overexpression inhibited both FAK and PYK2 phosphorylation and downstream signaling in vivo. To identify which kinase was involved in regulating VSMC invasion, adenovirally mediated expression of specific short hairpin RNAs was used to knock down FAK versus PYK2 in cultured VSMCs, but only FAK short hairpin RNA was effective in reducing VSMC invasion. The role of FRNK tyrosine phosphorylation was then examined using adenoviruses expressing nonphosphorylatable (Tyr168Phe-, Tyr232Phe-, and Tyr168,232Phe-) green fluorescent protein-FRNK mutants. wtFRNK and all FRNK mutants localized to FAs, but only Tyr168 phosphorylation was required for FRNK to inhibit invasion. Preventing Tyr168 phosphorylation also increased FRNK-paxillin interaction, as determined by coimmunoprecipitation, total internal reflection fluorescence microscopy, and fluorescence recovery after photobleaching. Furthermore, wtFRNK competed with FAK for binding to p130(Cas) (a critically important regulator of cell migration) and prevented its phosphorylation. However, Tyr168Phe-FRNK was unable to bind p130(Cas).

conclusionWe propose a 3-stage mechanism for FRNK inhibition: focal adhesion targeting, Tyr168 phosphorylation, and competition with FAK for p130 binding and phosphorylation, which are all required for FRNK to inhibit VSMC invasion.

Indexed as

AdenoviridaeAnimalsCarotid ArteriesCarotid Artery InjuriesCatheterizationCell MovementCells, CulturedCrk-Associated Substrate ProteinFocal Adhesion Kinase 2Focal Adhesion Protein-Tyrosine KinasesGreen Fluorescent ProteinsModels, AnimalMuscle, Smooth, VascularPhosphorylationProtein BindingProtein-Tyrosine KinasesCrk-Associated Substrate ProteinFAK-related nonkinaseFocal Adhesion Kinase 2Focal Adhesion Protein-Tyrosine KinasesGreen Fluorescent ProteinsProtein-Tyrosine KinasesRNA, Small Interfering

Identifiers

PMID21852560
PMCPMC3197899
OpenAlexW2128162574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.